Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03571256
Other study ID # TV50717-CNS-30060
Secondary ID 2017-002976-24
Status Completed
Phase Phase 3
First received
Last updated
Start date May 31, 2018
Est. completion date December 9, 2019

Study information

Verified date November 2021
Source Teva Branded Pharmaceutical Products R&D, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.


Recruitment information / eligibility

Status Completed
Enrollment 158
Est. completion date December 9, 2019
Est. primary completion date December 9, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Years to 16 Years
Eligibility Inclusion Criteria: - Participant weighs at least 44 pounds (20 kg) at baseline. - Participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5™) diagnostic criteria for TS and, in the opinion of the investigator, participant, and parent/legal guardian, the participant's active tics are causing distress or impairment. - Participant has a TTS of 20 or higher on the YGTSS at screening and baseline. - Participant is able to swallow study medication whole. - -Additional criteria apply, please contact the investigator for more information Exclusion Criteria: - Participant has a neurologic disorder other than TS that could obscure the evaluation of tics. - The participant 's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder. - Participant has clinically significant depression at screening or baseline. - Participant has a history of suicidal intent or related behaviors within 2 years of screening - Participant has a history of a previous actual, interrupted, or aborted suicide attempt. - Participant has a first-degree relative who has completed suicide. - Participant has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder. - Participant has received Comprehensive Behavioral Intervention for Tics for TS or Cognitive Behavioral Therapy for obsessive-compulsive disorder (OCD) within 4 weeks of screening. - Participant has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation within 4 weeks of the screening visit for reduction of tics. - Participant has a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure. - Participant has participated in an investigational drug or device study and received investigational medicinal product (IMP)/intervention within 30 days or 5 drug half-lives of baseline, whichever is longer. - Participant is a pregnant or lactating female, or plans to be pregnant during the study. - -Additional criteria apply, please contact the investigator for more information

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TEV-50717
6-, 9-, 12-, 15-, and 18 mg oral tablets
Placebo
Placebo matched to TEV-50717 tablets will be taken BID.

Locations

Country Name City State
Argentina Teva Investigational Site 060-1401 Buenos Aires
Argentina Teva Investigational Site 060-1402 Buenos Aires
Argentina Teva Investigational Site 060-1407 Buenos Aires
Argentina Teva Investigational Site 060-1403 La Plata
Argentina Teva Investigational Site 060-1404 Mendoza
Australia Teva Investigational Site 060-1802 Liverpool
Australia Teva Investigational Site 060-1801 Parkville
Colombia Teva Investigational Site 060-1503 Bello
Colombia Teva Investigational Site 060-1501 Medellin
Colombia Teva Investigational Site 060-1506 Medellin
Colombia Teva Investigational Site 060-1504 Pereira
Hungary Teva Investigational Site 060-0901 Budapest
Hungary Teva Investigational Site 060-0902 Szeged
Italy Teva Investigational Site 060-1005 Cagliari
Italy Teva Investigational Site 060-1001 Catania
Italy Teva Investigational Site 060-1003 Naples
Italy Teva Investigational Site 060-1004 Rome
Korea, Republic of Teva Investigational Site 060-1901 Seoul
Korea, Republic of Teva Investigational Site 060-1902 Seoul
Korea, Republic of Teva Investigational Site 060-1903 Seoul
Korea, Republic of Teva Investigational Site 060-1904 Seoul
Mexico Teva Investigational Site 060-1601 Culiacan
Mexico Teva Investigational Site 060-1603 Leon
Mexico Teva Investigational Site 060-1602 Monterrey
Mexico Teva Investigational Site 060-1604 Monterrey
Poland Teva Investigational Site 060-1104 Gdansk
Poland Teva Investigational Site 060-1101 Katowice
Poland Teva Investigational Site 060-1105 Krakow
Poland Teva Investigational Site 060-1102 Poznan
Poland Teva Investigational Site 060-1106 Torun
Poland Teva Investigational Site 060-1103 Warsaw
Ukraine Teva Investigational Site 060-2003 Dnipropetrovsk
Ukraine Teva Investigational Site 060-2001 Kharkiv
Ukraine Teva Investigational Site 060-2002 Kharkiv
Ukraine Teva Investigational Site 060-2007 Kiev
Ukraine Teva Investigational Site 060-2005 Kyiv
Ukraine Teva Investigational Site 060-2006 Vinnytsia
United States Teva Investigational Site 060-0165 Ann Arbor Michigan
United States Teva Investigational Site 060-0168 Atlanta Georgia
United States Teva Investigational Site 060-0170 Bridgeton Missouri
United States Teva Investigational Site 060-0169 Charleston South Carolina
United States Teva Investigational Site 060-0155 Chicago Illinois
United States Teva Investigational Site 060-0164 Chicago Illinois
United States Teva Investigational Site 060-0162 Everett Washington
United States Teva Investigational Site 060-0163 Fort Worth Texas
United States Teva Investigational Site 060-0160 Gainesville Florida
United States Teva Investigational Site 060-0166 Gulf Breeze Florida
United States Teva Investigational Site 060-0152 Indianapolis Indiana
United States Teva Investigational Site 060-0158 Louisville Kentucky
United States Teva Investigational Site 060-0157 Memphis Tennessee
United States Teva Investigational Site 060-0161 Miami Florida
United States Teva Investigational Site 060-0156 Nashville Tennessee
United States Teva Investigational Site 060-0154 New York New York
United States Teva Investigational Site 060-0151 Orlando Florida
United States Teva Investigational Site 060-0153 Orlando Florida
United States Teva Investigational Site 060-0167 Rockville Maryland

Sponsors (2)

Lead Sponsor Collaborator
Teva Branded Pharmaceutical Products R&D, Inc. Nuvelution TS Pharma, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Colombia,  Hungary,  Italy,  Korea, Republic of,  Mexico,  Poland,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated-measures (MMRM) with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates. Baseline, Week 8
Secondary Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates. Baseline, Week 8
Secondary Change From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates. Baseline, Week 8
Secondary Change From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates. Baseline, Week 8
Secondary Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy. Baseline, Week 8
Secondary Change From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy. Baseline, Week 8
Secondary Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants C&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates. Baseline, Week 8
Secondary Change From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants C&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates. Baseline, Week 8
Secondary Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version and Self-reported Version) Total Score at Week 9 CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children. Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors. Baseline, Week 9
Secondary Number of Participants at Baseline and Week 9 With Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module. Baseline, Week 9
See also
  Status Clinical Trial Phase
Recruiting NCT04851678 - Longitudinal Impact of Stressors in Adults With Tourette Syndrome
Completed NCT02605902 - Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders N/A
Completed NCT04007913 - Incorporating teleCBIT Into a Hospital-Based Tic Program N/A
Completed NCT02900144 - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) N/A
Completed NCT02216474 - Brain Stimulation in Movement Disorders N/A
Completed NCT02256475 - Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome Phase 1
Completed NCT01329198 - Brain Stimulation for the Treatment of Tourette Syndrome N/A
Terminated NCT00952601 - Pilot Study of the Modified Atkins Diet for Tourette Syndrome Phase 1
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00206323 - A Randomized, Placebo-controlled, Tourette Syndrome Study. Phase 3
Completed NCT00004376 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Phase 3
Completed NCT04498364 - Extinction Learning in Adults With Tourette Syndrome N/A
Completed NCT00755339 - Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
Completed NCT03325010 - Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT01702077 - Neurofeedback for Tourette Syndrome N/A
Completed NCT01719523 - Open-Trial of EPI-743 for Adults With Tourette Syndrome Phase 1
Completed NCT00231985 - Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder Phase 2
Completed NCT00206336 - An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Phase 3
Terminated NCT03732534 - Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome Phase 2